Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers

Annals of Surgery

Volumn 261, Issue 1, 2015, Pages 157-163

  Elias, Dominique ^a   Faron, Matthieu ^a   Iuga, Bogdan Stan ^a   Honoré, Charles ^a   Dumont, Frédéric ^a   Bourgain, Jean Louis ^d   Dartigues, Peggy ^c   Ducreux, Michel ^b   Goéré, Diane ^a  

^a Sanofi Aventis   (France)

^b Departments of Medical Oncology Gustave Roussy Cancer Campus   (France)

^c Pathology Department   (France)

^d Anesthesiology Department   (France)

Author keywords

Colorectal cancer; Liver metastases; Peritoneal carcinomatosis; Peritoneal metastases

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MORBIDITY; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RADIOFREQUENCY ABLATION; SURVIVAL RATE; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; COLORECTAL TUMOR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; SECONDARY;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84927169818     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000582     Document Type: Article

References (32)

1. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21: 3737-3743.
2. Franko J, ShiQ, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012; 30: 263-267.
3. Klaver YLB, Simkens LHJ, Lemmens VEPP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012; 38: 617-623.
4. Elias DM. Peritoneal carcinomatosis or liver metastases from colorectal cancer: similar standards for a curative surgery? Ann Surg Oncol. 2004; 11: 122-123.
5. Shen P, Thai K, Stewart JH, et al. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol. 2008; 15: 3422-3432.
6. Cao CQ, Yan TD, Liauw W, et al. Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis. J Surg Oncol. 2009; 100: 529-533.
7. Gertsch P.Ahistorical perspective on colorectal livermetastases and peritoneal carcinomatosis: similar results, different treatments. Surg Oncol Clin N Am. 2003; 12: 531-541.
8. Da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006; 203: 878-886.
9. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Franc?aise de Chirurgie. Cancer. 1996; 77: 1254-1262.
10. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997; 15: 938-946.
11. MitryE, FieldsALA, BleibergH, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008; 26: 4906-4911.
12. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371: 1007-1016.
13. Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007; 50: 478-488.
14. Goéré D, Benhaim L, Bonnet S, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg. 2013; 257: 114-120.
15. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010; 28: 63-68.
16. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004; 22: 3284-3292.
17. EliasD, Quenet F, GoéréD.Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am. 2012; 21: 611-623.
18. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318; discussion 318-321.
19. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003; 12: 165-192, xi.
20. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
21. Elias D, Lasser P, Debaene B, et al. Intermittent vascular exclusion of the liver (without vena cava clamping) during major hepatectomy. Br J Surg. 1995; 82: 1535-1539.
22. Elias D, Debaere T, Muttillo I, et al. Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection. J Surg Oncol. 1998; 67: 190-191.
23. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001; 92: 71-76.
24. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009; 27: 681-685.
25. Abdalla EK, Bauer TW, Chun YS, et al. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford). 2013; 15: 119-130.
26. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009; 27: 1829-1835.
27. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25: 4575-4580.
28. Quenet F, Goéré D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011; 254: 294-301.
29. Goéré D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013; 257: 1065-1071.
30. Elias D, Honoré C, Dumont F, et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg. 2011; 254: 289-293.
31. Honoré C, Goéré D, Souadka A, et al. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review. Ann Surg Oncol. 2013; 20: 183-192.
32. Maggiori L, Goéré D, Viana B, et al. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. Ann Surg. 2013; 258: 116-121.